BACKGROUND: Surgical resection is often the only treatment necessary for pediatric low-grade gliomas (LGGs) and is thought to define a population with an excellent long-term prognosis. The goal of this study was to describe the multidimensional late-effects of pediatric LGG survivors treated exclusively with surgery. METHODS: A retrospective chart review of "surgery-only" LGG survivors followed at Dana-Farber/Children's Hospital Cancer Care was undertaken. Patients had to be diagnosed with an LGG before the age of 22 years, treated with "surgery-only" and be at least 2 years from diagnosis. RESULTS: Sixty survivors were eligible with a median age at the time of review of 16.3 years and the median time since diagnosis of 8.4 years. Tumor locations were predominantly posterior fossa (47%) or cortical (33%). Eighty-five percent of patients had at least one ongoing late-effect, and 28% had three or more. The most common late-effects consisted of motor dysfunction (43%), visual problems (32%), anxiety (19%), social difficulties (19%), seizure disorders (17%), depression (15%), poor coordination/ataxia (14%), behavioral problems (13%), and endocrinopathies (10%). Nine patients had a history of suicidal ideation; two with suicide attempts. The mean full-scale IQ was normal, however, the number of survivors scoring one standard deviation below the mean was twice the expected number. Special education services were utilized by more than half of the survivors. CONCLUSIONS: "Surgery-only" LGG survivors may be more affected by their tumor and its resection than previously appreciated. A prospective study is needed to address this survivor population. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: Surgical resection is often the only treatment necessary for pediatric low-grade gliomas (LGGs) and is thought to define a population with an excellent long-term prognosis. The goal of this study was to describe the multidimensional late-effects of pediatric LGG survivors treated exclusively with surgery. METHODS: A retrospective chart review of "surgery-only" LGG survivors followed at Dana-Farber/Children's Hospital Cancer Care was undertaken. Patients had to be diagnosed with an LGG before the age of 22 years, treated with "surgery-only" and be at least 2 years from diagnosis. RESULTS: Sixty survivors were eligible with a median age at the time of review of 16.3 years and the median time since diagnosis of 8.4 years. Tumor locations were predominantly posterior fossa (47%) or cortical (33%). Eighty-five percent of patients had at least one ongoing late-effect, and 28% had three or more. The most common late-effects consisted of motor dysfunction (43%), visual problems (32%), anxiety (19%), social difficulties (19%), seizure disorders (17%), depression (15%), poor coordination/ataxia (14%), behavioral problems (13%), and endocrinopathies (10%). Nine patients had a history of suicidal ideation; two with suicide attempts. The mean full-scale IQ was normal, however, the number of survivors scoring one standard deviation below the mean was twice the expected number. Special education services were utilized by more than half of the survivors. CONCLUSIONS: "Surgery-only" LGG survivors may be more affected by their tumor and its resection than previously appreciated. A prospective study is needed to address this survivor population. (c) 2009 Wiley-Liss, Inc.
Authors: Fang Liu; Nadia Scantlebury; Uri Tabori; Eric Bouffet; Suzanne Laughlin; Douglas Strother; Dina McConnell; Juliette Hukin; Chris Fryer; Marie-Eve Brière; Isabelle Montour-Proulx; Daniel Keene; Frank Wang; Donald J Mabbott Journal: Neuro Oncol Date: 2014-11-13 Impact factor: 12.300
Authors: Sumedh Subodh Shah; Anna Dellarole; Eric Cecala Peterson; Amade Bregy; Ricardo Komotar; Philip D Harvey; Mohamed Samy Elhammady Journal: Childs Nerv Syst Date: 2015-03-01 Impact factor: 1.475
Authors: M Douglas Ris; Wendy M Leisenring; Pamela Goodman; Chongzhi Di; Jennie Noll; Wendy Levy; Leslie L Robison; Gregory T Armstrong Journal: Cancer Date: 2019-06-24 Impact factor: 6.860
Authors: Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Anuradha Banerjee; Roger J Packer; Lindsay B Kilburn; Stewart Goldman; Ian F Pollack; Ibrahim Qaddoumi; Regina I Jakacki; Paul G Fisher; Girish Dhall; Patricia Baxter; Susan G Kreissman; Clinton F Stewart; David T W Jones; Stefan M Pfister; Gilbert Vezina; Jessica S Stern; Ashok Panigrahy; Zoltan Patay; Benita Tamrazi; Jeremy Y Jones; Sofia S Haque; David S Enterline; Soonmee Cha; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi Journal: Lancet Oncol Date: 2019-05-28 Impact factor: 41.316
Authors: Gregory T Armstrong; Heather M Conklin; Sujuan Huang; Deokumar Srivastava; Robert Sanford; David W Ellison; Thomas E Merchant; Melissa M Hudson; Mary Ellen Hoehn; Leslie L Robison; Amar Gajjar; E Brannon Morris Journal: Neuro Oncol Date: 2010-12-22 Impact factor: 12.300
Authors: Inga M R Jóhannsdóttir; Marianne J Hjermstad; Torbjørn Moum; Finn Wesenberg; Lars Hjorth; Henrik Schrøder; Päivi Lähteenmäki; Gudmundur Jónmundsson; Jon H Loge Journal: J Cancer Surviv Date: 2010-01-16 Impact factor: 4.442